1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Bio Essence Corp.

Bio Essence Corp.

OOTC:BIOE
0.42
USD
0.00
(0.00%)
0.04EPS
7.65P/E
12.65MMarket Cap
Bio Essence Corp.
OTC:BIOE
(OTC Markets)

Recent

price

0.42

P/E

ratio

7.65

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.03
0.03
0.03
0.02
- -
0.01
0.05
0.07
Revenue per Share
-0.05
-0.02
-0.02
-0.02
-0.03
-0.03
0.02
0.04
Basic EPS, GAAP
-0.03
-0.02
-0.04
-0.02
-0.03
0.02
0.04
0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.03
-0.05
-0.07
-0.1
-0.04
-0.08
-0.05
0.05
Book Value per Share
-0.03
-0.05
-0.07
-0.1
-0.04
-0.08
-0.05
-0.02
Tangible Book Value per Share
33
33
33
33
34
38
38
43
Basic Weighted Avg Shares
1
1
1
1
- -
- -
2
3
Sales/Revenue/Turnover
-189.81
-86.65
-95.6
-82.23
- -
-141.83
47.43
52.86
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-1
-1
-1
-1
-1
1
2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
0.09
1.32
Effective Tax Rate (%)
-206.15
-62.15
-72.93
-130.26
- -
-404.02
47.23
52.12
Profit Margin (%)
-1
-2
-2
-3
-2
-3
-2
-1
Working Capital
1
1
1
1
1
- -
- -
- -
LT Debt
-1
-2
-2
-3
-2
-3
-2
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
89.45
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-232.79
89.76
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
47
47
Market Capitalization
2
6
13

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
1
1
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.92%
-30.18%
Free Cash Flow
- -
15.52%
151.62%
Net Income, GAAP
- -
-16.01%
-168.47%
Sales/Revenue/Turnover
- -
- -
485.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
1
2
2026
1
1
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.03
- -
-0.03
2025
-0.01
- -
- -
0.03
0.02
2026
- -
0.01
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Bio Essence Corporation (OTC Pink: BIOE), founded in 2000 and headquartered in Irvine, California, operates as a biotechnology and herbal health company focused on manufacturing and distributing health supplement products; it provides original equipment manufacturing (OEM) services, including compounding, encapsulation, tabletting, packaging, product development, ingredient sourcing, and testing; and serves healthcare practitioners through holistic wellness solutions such as custom formulations, online pharmacy platforms, and in-person clinics offering spa-like environments for patient care. The company targets healthcare professionals and consumers seeking herbal health, diet, nutrition, vitamin supplements, traditional Chinese medicine (TCM) herbs, anti-aging products, men's health, women's health, optic health, and sleep health offerings, with operations primarily in the United States and capabilities for international export. Bio Essence maintains an in-house R&D team augmented by partnerships with top-tier healthcare professionals and a medical advisory board to drive innovation in biotech and wellness products. In recent major changes, the company completed the sale of its subsidiaries Bio Essence Pharmaceutical Inc. and Bio Essence Herbal Essentials Inc. for $700,000 in 2024, recording a gain on the disposal of Bio Essence Herbal Essentials Inc.; dissolved other subsidiaries including Fusion Naturals and McBE Pharma to streamline operations; shifted to direct management and outsourced manufacturing while focusing on expanding its OEM business; and executed a significant debt-to-equity conversion where CEO Yin Yan received 5,000,000 shares for retiring $2,500,000 in debt. These strategic restructurings aim to enhance profitability amid financial challenges, with management planning increased sales efforts, marketing enhancements, and pursuit of additional funding or acquisition opportunities.

Company News

Company News APIChatGPT

  • accessnewswire.com

    Bio Essence Corporation Expands MediFlow Platform with Development of Practitioner-Specific AI and RAG Technology

  • accessnewswire.com

    Bio Essence Corporation (OTCQB: BIOE) to Acquire MediFlow AI Platform, Strengthening Its Human Health and Wellness Portfolio

  • accessnewswire.com

    BIO ESSENCE CORP (OTCQB:BIOE) Announces Approval for Upgrade to the OTCQB Market, Effective February 26, 2026